Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001703
Chunk: 3

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 3
---
 to a number of risks and uncertainties. All statements that are not historical facts are forward-looking
statements. Forward-looking statements can generally be identified by the use of words such as “continue,” “expect,”
“will,” “plan,” “would” and similar expressions, or the negatives thereof, or they may use future
dates. Forward-looking statements made in this document include statements regarding expected contributions from our current directors,
expectations regarding delivering value for our stockholders, market share and size of the market, our business strategy and long-term
performance. Actual results may differ materially from those set forth in this communication due to the risks and uncertainties
inherent in our business, including, the risk that circumstances

Page 2 of 4

surrounding or leading up to our 2025 Annual Meeting may change,
risks relating to our ability to commercialize and supply HEPLISAV-B, the risks that market size or actual demand for our products
may differ from our expectations, risks related to the timing of completion and results of current clinical studies,risks related to the development and pre-clinical and clinical testing of vaccines containing CpG 1018 adjuvant, and risks
related to the implementation of our long-term growth objectives, as well as other risks detailed in the “Risk Factors”
section of our Quarterly Report on Form 10-Q for the three months ended March 31, 2025 and any periodic filings made thereafter,
as well as discussions of potential risks, uncertainties and other important factors in our other filings with the U.S. Securities
and Exchange Commission. These forward-looking statements are made as of the date hereof, are qualified in their entirety by this
cautionary statement and we undertake no obligation to revise or update information herein to reflect events or circumstances in
the future, even if new information becomes available. Information on Dynavax’s website at www.dynavax.com is not incorporated
by reference in our current periodic reports with the SEC.

Important Additional Information and Where to Find It

On April 17, 2025, the Company filed a definitive proxy statement
on Schedule 14A (the “Proxy Statement”) and form of accompanying GOLD proxy card with the U.S. Securities and Exchange
Commission (the “SEC”) in connection with its 2025 Annual Meeting and its solicitation of proxies for the Company’s
director nominees and for other matters to be voted on. The Company may also file other relevant documents with the SEC regarding
its solicitation of